Rubitecan

Bibliography

• PIZZOLATO JF, SALTZ LB: The camptothecins. Lancet (2003) 361(9376):2235-2242.
   Google Scholar
• RASHEED ZA, RUBIN EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene (2003) 22(47):7296-7304.
   Google Scholar
• KUPPENS IE, BEIJNEN J, SCHELLENS JH: Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin. Colorectal Cancer (2004) 4(3):163-180.
   PubMedGoogle Scholar
• GARCIA-CARBONERO R, SUPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. (2002) 8(3):641-661.
   PubMed Web of Science ®Google Scholar
• PRATESI G, BERETTA GL, ZUNINO F: Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs (2004) 15(6):545-552.
   Google Scholar
• MILLER AA, HERNDON JE II, GU L, GREEN MR: Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer (2005) 48(3):399-407.
   Google Scholar
• GELDERBLOM H, SALAZAR R, VERWEIJ J et al.: Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin. Cancer Res. (2003) 9(11):4101-4107.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, SERYSHEV A, KNIGHT V, BRAYTON C: 9-Nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal. Toxicol. (2002) 14(2):185-197.
   PubMed Web of Science ®Google Scholar
• VERSCHRAEGEN CF, JAECKLE K, GIOVANELLA B, KNIGHT V, GILBERT BE: Alternative administration of camptothecin analogues. Ann. NY Acad. Sci. (2000) 922:237-246.
   PubMed Web of Science ®Google Scholar
• DERAKHSHANDEH K, DADASHZADEH S: Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2005) 818(2):199-204.
   PubMed Web of Science ®Google Scholar
• ZAMBONI WC, JUNG LL, EGORIN MJ et al.: Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clin. Cancer Res. (2005) 11(13):4867-4874.
   PubMed Web of Science ®Google Scholar
• CAO ZS, PANTAZIS P, MENDOZA J et al.: Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Acta Pharmacol. Sin. (2003) 24(2):109-119.
   PubMed Web of Science ®Google Scholar
• GIOVANELLA BC, STEHLIN JS, HINZ HR et al.: Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (rubitecan). Int. J. Oncol. (2002) 20(1):81-88.
   PubMed Web of Science ®Google Scholar
• GIOVANELLA BC, HINZ HR, KOZIELSKI AJ et al.: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. (1991) 51(11):3052-3055.
   PubMed Web of Science ®Google Scholar
• RUBIN E, WOOD V, BHARTI A et al.: A Phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. (1995) 1(3):269-276.
   PubMed Web of Science ®Google Scholar
• TIAN Q, ZHANG J, TAN TM et al.: Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. (2005) (In Press).
   Google Scholar
• JUNG LL, RAMANATHAN RK, EGORIN MJ et al.: Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother. Pharmacol. (2004) 54(6):487-496.
   PubMed Web of Science ®Google Scholar
• ZAMBONI WC, JUNG LL, EGORIN MJ et al.: Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin. Cancer Res. (2004) 10(15):5058-5064.
   PubMed Web of Science ®Google Scholar
• GOUNDER MK, SUN SL, SANDS H et al.: Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2004) 799(1):63-72.
   PubMed Web of Science ®Google Scholar
• SCHOEMAKER NE, MATHOT RA, SCHOFFSKI P et al.: Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemother. Pharmacol. (2002) 50(6):514-517.
   PubMed Web of Science ®Google Scholar
• SCHOFFSKI P, HERR A, VERMORKEN JB et al.: Clinical Phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur. J. Cancer (2002) 38(6):807-813.
   PubMed Web of Science ®Google Scholar
• ZAMBONI WC, GOEL S, IQBAL T et al.: Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chemother. Pharmacol. (2005):1-9.
   Google Scholar
• LI K, CHEN X, ZHONG D, LI Y: Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats. Drug Metab. Dispos. (2003) 31(6):792-797.
   PubMed Web of Science ®Google Scholar
• ZHONG DF, LI K, XU JH, DU Y, ZHANG YF: Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Acta Pharmacol. Sin. (2003) 24(3):256-262.
   PubMed Web of Science ®Google Scholar
• GIOVANELLA BC, STEHLIN JS, WALL ME et al.: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (1989) 246(4933):1046-1048.
   Google Scholar
• BERNACKI RJ, PERA P, GAMBACORTA P, BRUN Y, GRECO WR: In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Ann. NY Acad. Sci. (2000) 922:293-297.
   PubMed Web of Science ®Google Scholar
• KOSHKINA NV, GILBERT BE, WALDREP JC, SERYSHEV A, KNIGHT V: Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol. (1999) 44(3):187-192.
   PubMed Web of Science ®Google Scholar
• LAWSON KA, ANDERSON K, SNYDER RM et al.: Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother. Pharmacol. (2004) 54(5):421-431.
   PubMed Web of Science ®Google Scholar
• TEDESCO KL, BERLIN J, ROTHENBERG M et al.: A Phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin™) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother. Oncol. (2005) 76(1):54-58.
   PubMed Web of Science ®Google Scholar
• PANTAZIS P, HAN Z, BALAN K, WANG Y, WYCHE JH: Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models. Anti-Cancer Res. (2003) 23(5A):3623-3638.
   PubMed Web of Science ®Google Scholar
• KIM JS, AMORINO GP, PYO H, CAO Q, CHOY H: Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother. Oncol. (2002) 62(1):61-67.
   PubMed Web of Science ®Google Scholar
• AMORINO GP, HERCULES SK, MOHR PJ, PYO H, CHOY H: Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. (2000) 47(2):503-509.
   PubMed Web of Science ®Google Scholar
• PANTAZIS P, CHATTERJEE D, HAN Z, WYCHE J: Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells. Anticancer Drugs (1999) 10(3):317-322.
   Google Scholar
• NATELSON EA, GIOVANELLA BC, VERSCHRAEGEN CF et al.: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann. NY Acad. Sci. (1996) 803:224-230.
   PubMed Web of Science ®Google Scholar
• VERSCHRAEGEN CF, NATELSON EA, GIOVANELLA BC et al.: A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs (1998) 9(1):36-44.
   Google Scholar
• VERSCHRAEGEN CF, GILBERT BE, LOYER E et al.: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. (2004) 10(7):2319-2326.
   PubMed Web of Science ®Google Scholar
• CALVO E, ROWINSKY EK, TOLCHER AW et al.: A Phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. J. Clin. Oncol. (2004) 22(14S):2099 (Abstract).
   Google Scholar
• MICHAELSON MD, RYAN DP, FUCHS CS et al.: A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer (2003) 97(1):148-154.
   Google Scholar
• VERSCHRAEGEN CF, VINCENT M, ABBRUZZESE JL et al.: Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. Ann. NY Acad. Sci. (2000) 922:345-348.
   PubMed Web of Science ®Google Scholar
• FRACASSO PM, RADER JS, GOVINDAN R et al.: Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann. Oncol. (2002) 13(11):1819-1825.
   PubMed Web of Science ®Google Scholar
• STEHLIN JS, GIOVANELLA BC, NATELSON EA et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol. (1999) 14(5):821-831.
   PubMed Web of Science ®Google Scholar
• KONSTADOULAKIS MM, ANTONAKIS PT, TSIBLOULIS BG et al.: A Phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. (2001) 48(5):417-420.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, RIVKIN S, REYNOLDS R et al.: Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist (2005) 10(3):183-190.
   Google Scholar
• VERSCHRAEGEN CF, GUPTA E, LOYER E et al.: A Phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs (1999) 10(4):375-383.
   Google Scholar
• PUNT CJ, DE JONGE MJ, MONFARDINI S et al.: RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a Phase II study of the EORTC New Drug Development Group. Eur. J. Cancer (2004) 40(9):1332-1334.
   PubMed Web of Science ®Google Scholar
• BAKA S, RANSON M, LORIGAN P et al.: A Phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Eur. J. Cancer (2005) 41(11):1547-1550.
   PubMed Web of Science ®Google Scholar
• AMIN A, HALABI S, GELMANN EP et al.: 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: results of the CALGB 99901. Urol. Oncol. (2004) 22(5):398-403.
   PubMed Web of Science ®Google Scholar
• DE JONGE MJ, DROZ JP, PAZ-ARES L et al.: Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Invest. New Drugs (2004) 22(3):329-333.
   PubMed Web of Science ®Google Scholar
• MILLER KD, SOULE SE, HANEY LG et al.: A Phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Invest. New Drugs (2004) 22(1):69-73.
   PubMed Web of Science ®Google Scholar
• CHEDID S, RIVERA E, FRYE DK et al.: Minimal clinical benefit of single agent Orathecin™ (rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother. Pharmacol. (2005):1-5.
   Google Scholar
• CHUGH R, DUNN R, ZALUPSKI MM et al.: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J. Clin. Oncol. (2005) 23(15):3597-3604.
   PubMed Web of Science ®Google Scholar
• PATEL SR, BEACH J, PAPADOPOULOS N et al.: Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer (2003) 97(11):2848-2852.
   Google Scholar
• RAYMOND E, CAMPONE M, STUPP R et al.: Multicentre Phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer (2002) 38(10):1348-1350.
   PubMed Web of Science ®Google Scholar
• ELLERHORST JA, BEDIKIAN AY, SMITH TM et al.: Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs (2002) 13(2):169-172.
   Google Scholar
• JACOBS A, BURRIS, HA, RIVKIN, S, RITCH, PS, EISENBERG PD, METTINGER KL: A randomized Phase III study of rubitecan (ORA) versus best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J. Clin. Oncol. (2004) 22(14S):4013 (Abstract).
   Google Scholar
• PAPISH S, RAMANATHAN R, PINCUS J, HIRMAND M, BURRIS HA: Patients rescued by crossover to rubitecan in Phase III study of rubitecan capsules versus 5-FU in pancreatic cancer. Am. Soc. Clin. Oncol. (2005):4165 (Abstract).
   Google Scholar
• CHEVERTON P, FRIESS H, ANDRAS C et al.: Phase III results of exatecan (DX-89511) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). J. Clin. Oncol. (2004) 22(14S):4005 (Abstract).
   Google Scholar
• REILLY E, ABOU-ALFA GK, LETOURNEAU R et al.: A randomized Phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) versus gemcitabine alone in advanced pancreatic cancer (APC). J. Clin. Oncol. (2004) 22(14S):4006 (Abstract).
   Google Scholar
• ROCHA LIMA CM, GREEN MR, ROTCHE R et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. (2004) 22(18):3776-3783.
   PubMed Web of Science ®Google Scholar